Related Experiment Videos
LY-293558. Eli Lilly & Co
1Departments of Anesthesiology and Pharmacology & Toxicology, Queen's University, Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada. gilroni@post.queensu.ca
Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
Abstract:
Lilly is developing the racemic compound LY-215490, a selective and competitive AMPA antagonist, as a potential treatment for cerebral infarction, cerebrovascular ischemia, epilepsy and as an analgesic [135089], [158980], [254029], [278691]. By January 2000, LY-293558 was undergoing phase II trials for pain [414000].